Scleroderma — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Injectable platelet-rich fibrin as a valid therapeutic option for inactive linear morphea (en coup de saber): report of cases.
Ai Xuechen et al. — The Journal of dermatological treatment (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41773608/
- 2.
Dual-channel self-supervised multi-task learning for spectral detection of soluble solids content and firmness in Korla fragrant pears.
Bu Youhua et al. — Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy (5 July 2026)
https://pubmed.ncbi.nlm.nih.gov/41797164/
- 3.
Activity-Based Functional Exercise for Disability in Systemic Sclerosis: Protocol for a Feasibility Randomised Controlled Trial.
da Silva Santos Gabriela et al. — Musculoskeletal care (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41912277/
- 4.
Soluble immune checkpoints reflect immune activation and treatment response in high-risk systemic sclerosis patients treated with plasma exchange.
Potjewijd Judith et al. — Journal of translational autoimmunity (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41782636/
- 5.
Rapid quality detection in colored potatoes during alternating cold and ambient storage: Utilizing absorption and scattering properties.
Xiao Yuanji et al. — Food research international (Ottawa, Ont.) (31 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41895990/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study of AZD0120 in Autoimmune Diseases
Recruiting — Phase 1 — AstraZeneca
https://clinicaltrials.gov/study/NCT07295847
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Scleroderma
Scleroderma (systemic sclerosis) is a rare autoimmune connective tissue disease characterised by fibrosis of the skin and internal organs, vascular abnormalities, and immune dysregulation. It ranges from limited cutaneous to diffuse forms with major organ involvement. Interstitial lung disease and pulmonary arterial hypertension are leading causes of disease-related mortality.
Most Recent Research
OBJECTIVES: Localized scleroderma, also called morphea, is an inflammatory cutaneous disorder characterized by sclerosis of the skin and underlying tissues. Morphea is currently classified into 4 subtypes: limited, generalized, linear and mixed. Linear morphea in an en coup de saber pattern (LScs) manifests as band-like, atrophic lesions predominantly affecting the frontoparietal area, leading to facial contour defects and skin pigmentation. However, pharmacological treatments for LScs are limited in meeting the aesthetic expectations of patients. Recently, autologous platelet concentrates have shown great therapeutic potential for tissue regeneration and wound healing, while few studies have been conducted on their use in LScs patients. METHODS AND RESULTS: We present the first report of two patients with inactive LScs that were improved by treatment with injectable platelet-rich fibrin (i-PRF), a second-generation autologous platelet concentrate. Satisfactory aesthetic outcomes were both achieved in two patients within 5 injection sessions, with only mild pain and transient erythema after injection. CONCLUSIONS: Injectable platelet-rich fibrin can be a novel, valid therapeutic alternative for morphea management.
Common Questions
What is Scleroderma?
Scleroderma (systemic sclerosis) is a rare autoimmune connective tissue disease characterised by fibrosis of the skin and internal organs, vascular abnormalities, and immune dysregulation. It ranges from limited cutaneous to diffuse forms with major organ involvement. Interstitial lung disease and pulmonary arterial hypertension are leading causes of disease-related mortality.
How many clinical trials are available for Scleroderma?
RareWays currently indexes 92 clinical trials for Scleroderma, of which 31 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Scleroderma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Scleroderma.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.